



# SM07883, a novel, oral DYRK1A kinase inhibitor, reduced tau pathology and associated behavioral deficits in preclinical models


## Specifically inhibited DYRK1A and reduced pTau *in vitro*

### Kinases within 15-fold of DYRK1A IC<sub>50</sub>



‡ Measured by immunoassays  
Note: EC<sub>50</sub> = average across multiple assays


## Inhibited tau pathology in JNPL3 mouse brains



Only 3 mg/kg normalized by β-actin


## Inhibited tau pathology in JNPL3 mouse brains

### Tau-positive Inclusions (Brainstem)







## Inhibited tau pathology in 3xTg-AD mouse brains

### Tau-positive Inclusions (Hippocampus)







# SM07883 reduced neurodegeneration-induced neuroinflammation in transgenic mouse models

**JNPL3**





**3xTg-AD**






# SM07883 significantly reduced functional and cognitive deficits in transgenic mouse models

JNPL3



■ Wild-type + Vehicle    ■ Vehicle    ■ 3 mg/kg/day SM07883

3xTg-AD



■ Wild-type + Vehicle    ■ Vehicle    ■ 5 mg/kg/day SM07883